Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
PEGPH20
Description:
PEGPH20 is a polyethylene glycol-modified form of human hyaluronidase studied as an enzyme therapy to degrade hyaluronan in cancer.
Primary topic:
Proteoglycans and glycosaminoglycans research (38%)
Related topics:
Proteoglycans and glycosaminoglycans research (38%),
Pancreatic and Hepatic Oncology Research (37%)
OpenAlex ID:
keywords/pegph20
Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer
2012
·
Michael A Jacobetz
, Derek S Chan
, et al.
·
Gut
·
1,231
PDF
Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma
2020
·
Eric Van Cutsem
, Margaret A. Tempero
, et al.
·
Journal of Clinical Oncology
·
584
PDF
HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma
2017
·
Sunil R. Hingorani
, Lei Zheng
, et al.
·
Journal of Clinical Oncology
·
559
Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer
2016
·
Sunil R. Hingorani
, William P. Harris
, et al.
·
Clinical Cancer Research
·
359
Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313
2019
·
Ramesh K. Ramanathan
, Shannon L. McDonough
, et al.
·
Journal of Clinical Oncology
·
357
Enzymatic Depletion of Tumor Hyaluronan Induces Antitumor Responses in Preclinical Animal Models
2010
·
Curtis B. Thompson
, H. Michael Shepard
, et al.
·
Molecular Cancer Therapeutics
·
317
Interstitial Pressure in Pancreatic Ductal Adenocarcinoma Is Dominated by a Gel-Fluid Phase
2016
·
Christopher C. DuFort
, Kathleen E. DelGiorno
, et al.
·
Biophysical Journal
·
182
PDF
HALO-109–301: a Phase III trial of PEGPH20 (with Pemcitabine and Nab-Paclitaxel) in Hyaluronic Acid-High Stage IV Pancreatic Cancer
2017
·
Gary J Doherty
, Margaret Tempero
, et al.
·
Future Oncology
·
165
Tumor-Associated Hyaluronan Limits Efficacy of Monoclonal Antibody Therapy
2015
·
Netai C. Singha
, Tara Nekoroski
, et al.
·
Molecular Cancer Therapeutics
·
150
Targeting the Tumor Stroma: the Biology and Clinical Development of Pegylated Recombinant Human Hyaluronidase (PEGPH20)
2017
·
Kit Man Wong
, Kathryn J. Horton
, et al.
·
Current Oncology Reports
·
145
Hyaluronan Accumulates With High-Fat Feeding and Contributes to Insulin Resistance
2013
·
Li Kang
, Louise Lantier
, et al.
·
Diabetes
·
142
HALO 109-301: A randomized, double-blind, placebo-controlled, phase 3 study of pegvorhyaluronidase alfa (PEGPH20) + nab-paclitaxel/gemcitabine (AG) in patients (pts) with previously untreated hyaluronan (HA)-high metastatic pancreatic ductal adenocarcinoma (mPDA).
2020
·
Margaret A. Tempero
, Eric Van Cutsem
, et al.
·
Journal of Clinical Oncology
·
135
Accumulation of Extracellular Hyaluronan by Hyaluronan Synthase 3 Promotes Tumor Growth and Modulates the Pancreatic Cancer Microenvironment
2014
·
Anne Kultti
, Chunmei Zhao
, et al.
·
BioMed Research International
·
132
PDF
Why HALO 301 Failed and Implications for Treatment of Pancreatic Cancer
2019
·
Nausheen Hakim
, Rajvi Patel
, et al.
·
Pancreas - Open Journal
·
113
PDF
Parallel Accumulation of Tumor Hyaluronan, Collagen, and Other Drivers of Tumor Progression
2018
·
Xiaoming Li
, H. Michael Shepard
, et al.
·
Clinical Cancer Research
·
98
Dissecting the Stromal Signaling and Regulation of Myeloid Cells and Memory Effector T Cells in Pancreatic Cancer
2019
·
Alex B. Blair
, Victoria M. Kim
, et al.
·
Clinical Cancer Research
·
90
Targeting Tumor Architecture to Favor Drug Penetration: A New Weapon to Combat Chemoresistance in Pancreatic Cancer?
2012
·
Man Yu
, Ian F. Tannock
·
Cancer Cell
·
90
PDF
Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours
2017
·
Jeffrey R Infante
, Ronald L Korn
, et al.
·
British Journal of Cancer
·
83
PDF
Remodeling the Tumor Microenvironment Sensitizes Breast Tumors to Anti-Programmed Death-Ligand 1 Immunotherapy
2019
·
Renee Clift
, Jennifer Souratha
, et al.
·
Cancer Research
·
79
Breaching the Castle Walls: Hyaluronan Depletion as a Therapeutic Approach to Cancer Therapy
2015
·
H. Michael Shepard
·
Frontiers in Oncology
·
78
PDF
Dual Stromal Targeting Sensitizes Pancreatic Adenocarcinoma for Anti-Programmed Cell Death Protein 1 Therapy
2022
·
Alex B. Blair
, Jianxin Wang
, et al.
·
Gastroenterology
·
77
PDF
Salmonella -Based Therapy Targeting Indoleamine 2,3-Dioxygenase Coupled with Enzymatic Depletion of Tumor Hyaluronan Induces Complete Regression of Aggressive Pancreatic Tumors
2015
·
Edwin R. Manuel
, Jeremy Chen
, et al.
·
Cancer Immunology Research
·
73
Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform
2023
·
Andrew H Ko
, Kyu-Pyo Kim
, et al.
·
The Oncologist
·
70
PDF
Effective targeting of the tumor microenvironment for cancer therapy.
2012
·
Ping Jiang
, Xiaoming Li
, et al.
·
PubMed
·
68
PEGylated recombinant human hyaluronidase (PEGPH20) pre-treatment improves intra-tumour distribution and efficacy of paclitaxel in preclinical models
2021
·
Lavinia Morosi
, Marina Meroni
, et al.
·
Journal of Experimental & Clinical Cancer Research
·
66
PDF
Show more works
View as search
Works count:
223
Citation count:
6,287
Year
Topic
Type